SRSF5 Regulates the Expression of BQ323636.1 to Modulate Tamoxifen Resistance in ER-Positive Breast Cancer

• Published in: Cancers Vol. 15; no. 8; p. 2271
• Main Authors: Tsoi, Ho, Fung, Nicholas Nok-Ching, Man, Ellen P. S., Leung, Man-Hong, You, Chan-Ping, Chan, Wing-Lok, Chan, Sum-Yin, Khoo, Ui-Soon
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 13.04.2023; MDPI
• Subjects: Alternative splicing; Breast cancer; Cancer therapies; Cell cycle; Dosage and administration; Drug resistance; Drug therapy; Endocrine therapy; Estrogen receptors; Gene expression; Genetic aspects; Genetic regulation; Health aspects; Kinases; Metastases; Metastasis; mRNA; Phosphorylation; Plasmids; Proteins; Tamoxifen; Hong Kong, China; St Louis Missouri; United States > US; novel target; breast cancer; tamoxifen resistance; SRSF5; BQ323636.1; SRPK1

About 70% of breast cancer patients are oestrogen receptor-positive (ER +ve). Adjuvant endocrine therapy using tamoxifen (TAM) is an effective approach for preventing local recurrence and metastasis. However, around half of the patients will eventually develop resistance. Overexpression of BQ323636....